A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin

Fornaro, Michele; Maremmani, Angelo Giovanni Icro; Colicchio, Maria Giovanna; Romano, Anna; Fornaro, Stefania; Rizzato, Salvatore; Ciampa, G.; Colicchio, Salvatore; Dell’Osso, Liliana

doi:10.1016/j.genhosppsych.2011.10.003

Cited by 7 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 144 In one case study, a 54-year-old man with TS with self-injury presented with fibromyalgia, comorbid OCD, and self-injurious behaviors (tongue self-mutilation). 145 The patient was resistant to SSRIs, clomipramine, and haloperidol. Pregabalin monotherapy 600 mg/day was administered given the history of fibromyalgia and failure of other approaches; it was successful in improving self-injurious behaviors over 52 weeks of use.…”

Section: Clinical Trials Of Glutamate-modulating Drugs In Tsmentioning

confidence: 98%

See 1 more Smart Citation

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

Grados¹,

Atkins²,

Kovacikova³

et al. 2015

PRBM

View full text Add to dashboard Cite

Glutamate, an excitatory central nervous system neurotransmitter, is emerging as a potential alternative pharmacological treatment when compared to gamma-aminobutyric acid (GABA)-, dopamine-, and serotonin-modulating treatments for neuropsychiatric conditions. The pathophysiology, animal models, and clinical trials of glutamate modulation are explored in disorders with underlying inhibitory deficits (cognitive, motor, behavioral) including obsessive–compulsive disorder, attention deficit hyperactivity disorder, Tourette syndrome, trichotillomania, excoriation disorder, and nail biting. Obsessive–compulsive disorder, attention deficit hyperactivity disorder, and grooming disorders (trichotillomania and excoriation disorder) have emerging positive data, although only scarce controlled trials are available. The evidence is less supportive for the use of glutamate modulators in Tourette syndrome. Glutamate-modulating agents show promise in the treatment of disorders of inhibition.

show abstract

Section: Clinical Trials Of Glutamate-modulating Drugs In Tsmentioning

confidence: 98%

“…Pregabalin monotherapy 600 mg/day was administered given the history of fibromyalgia and failure of other approaches; it was successful in improving self-injurious behaviors over 52 weeks of use. 145 …”

Section: Clinical Trials Of Glutamate-modulating Drugs In Tsmentioning

confidence: 99%

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

Grados¹,

Atkins²,

Kovacikova³

et al. 2015

PRBM

View full text Add to dashboard Cite

show abstract

“…After reading the full text of the relevant articles, a total of 43 studies were found to meet the inclusion criteria for this systematic review. Of these, 33 articles were deemed suitable for inclusion based on their methodology: 20 cohort studies (Nee et al, 1980;Stefl, 1984;Robertson et al, 1989;Wand et al, 1993;Berthier et al, 1998;Lichter et al, 1999;Freeman et al, 2000;Cath et al, 2001;Robertson et al, 2002;Ohta and Kano, 2003;Eapen et al, 2004;Mathews et al, 2004;Martino et al, 2007;Robertson et al, 2008;Haddad et al, 2009;Kano et al, 2010;Szejko et al, 2019), 1 combined cohort study plus case series (Cheung et al, 2007), 2 case series (Muller-Vahl et al, 2000;Cavanna et al, 2010), and 10 case reports Anandan et al, 2004;Hood et al, 2004;Lim et al, 2004;Leksell and Edvardson, 2005;Bajwa et al, 2007;Banda et al, 2009;Cavanna et al, 2009;Duits et al, 2012;Fornaro et al, 2012). The process leading to the identification, screening, assessment of eligibility, and inclusion of studies is summarised in a PRISMA flow chart (Moher et al, 2009) (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome

Stafford

Cavanna

2020

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Link to publication on Research at Birmingham portal General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.• Users may freely distribute the URL that is used to identify this publication.• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

“…Agents such as gabapentin and pregabalin are related medications, which act on the alpha2‐delta protein, an auxiliary subunit of voltage‐gated calcium channels. They were initially designed as antiepileptics, but have found a potential use in psychiatry as antianxiety agents for treatment of self‐harm behavior and neuropathic pain and have been used off label in dystonia and dyskinetic movement disorders . Gabapentin has been noted to be beneficial in children with severely disabling dystonia, particularly if manifesting with pain or dystonic spasms.…”

Section: Symptomatic Therapiesmentioning

confidence: 99%

Current therapies and therapeutic decision making for childhood‐onset movement disorders

2019

View full text Add to dashboard Cite

Movement disorders differ in children to adults. First, neurodevelopmental movement disorders such as tics and stereotypies are more prevalent than parkinsonism, and second, there is a genomic revolution which is now explaining many early‐onset dystonic syndromes. We outline an approach to children with movement disorders starting with defining the movement phenomenology, determining the level of functional impairment due to abnormal movements, and screening for comorbid psychiatric conditions and cognitive impairments which often contribute more to disability than the movements themselves. The rapid improvement in our understanding of the etiology of movement disorders has resulted in an increasing focus on precision medicine, targeting treatable conditions and defining modifiable disease processes. We profile some of the key disease‐modifying therapies in metabolic, neurotransmitter, inflammatory, and autoimmune conditions and the increasing focus on gene or cellular therapies. When no disease‐modifying therapies are possible, symptomatic therapies are often all that is available. These classically target dopaminergic, cholinergic, alpha‐adrenergic, or GABAergic neurochemistry. Increasing interest in neuromodulation has highlighted that some clinical syndromes respond better to DBS, and further highlights the importance of “disease‐specific” therapies with a future focus on individualized therapies according to the genomic findings or disease pathways that are disrupted. We summarize some pragmatic applications of symptomatic therapies, neuromodulation techniques, and some rehabilitative interventions and provide a contemporary overview of treatment in childhood‐onset movement disorders. © 2019 International Parkinson and Movement Disorder Society

show abstract

A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin

Cited by 7 publications

References 15 publications

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome

Current therapies and therapeutic decision making for childhood‐onset movement disorders

Contact Info

Product

Resources

About

A case of severe oral self-injurious Tourette's syndrome alleviated by pregabalin

Cited by 7 publications

References 15 publications

A selective review of glutamate pharmacological therapy in obsessive&ndash;compulsive and related disorders

A selective review of glutamate pharmacological therapy in obsessive&ndash;compulsive and related disorders

Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome

Current therapies and therapeutic decision making for childhood‐onset movement disorders

Contact Info

Product

Resources

About

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders

A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders